isoniazid and pa 824

isoniazid has been researched along with pa 824 in 46 studies

Research

Studies (46)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	7 (15.22)	29.6817
2010's	36 (78.26)	24.3611
2020's	3 (6.52)	2.80

Authors

Authors	Studies
Anderson, SW; Arain, TM; Baker, WR; Barry, CE; Kreiswirth, BN; Langhorne, MH; McMurray, DN; Sherman, DR; Stover, CK; Towell, JA; VanDevanter, DR; Warrener, P; Yuan, Y	1
Hashizume, H; Kawasaki, M; Komatsu, M; Matsumoto, M; Sasaki, H; Shimokawa, Y; Tomishige, T; Tsubouchi, H	1
Cho, SH; Franzblau, SG; Hwang, CH; Pauli, GF; Wan, B; Warit, S	1
Aldana, I; Burguete, A; Cho, SH; Franzblau, SG; Goldman, RC; Lenaerts, AJ; Maddry, JA; Monge, A; Pérez-Silanes, S; Solano, B; Vicente, E; Villar, R	1
Franzblau, SG; Kozikowski, AP; Lilienkampf, A; Pieroni, M; Wan, B; Wang, Y	1
Chibale, K; Franzblau, SG; Guantai, EM; Gut, J; Hans, RH; Lategan, C; Rosenthal, PJ; Smith, PJ; Wan, B	1
Charnock, C; Franzblau, S; Gundersen, LL; Khoje, AD; Kulendrn, A; Wan, B	1
Chibale, K; Franzblau, SG; Gut, J; Hans, RH; Rosenthal, PJ; van Helden, PD; Wan, B; Wiid, IJ	1
Balzarini, J; Chibale, K; Franzblau, S; Singh, K; Wan, B	1
Charnock, C; Franzblau, S; Gundersen, LL; Khoje, AD; Wan, B	1
Boshoff, H; Cho, S; Franzblau, SG; Hipskind, PA; Markley, LD; Miller, MJ; Moraski, GC	1
Franzblau, SG; Garcia, GA; Gill, SK; Jin, Y; Kirchhoff, PD; Showalter, HD; Wan, B	1
Chen, L; Franzblau, SG; Liu, X; Lu, X; Wan, B; You, Q; Zhou, C	1
Boshoff, H; Chang, M; Cho, S; Franzblau, SG; Hwang, CH; Markley, LD; Miller, MJ; Moraski, GC	1
Baulard, AR; Crauste, C; Déprez, B; Flipo, M; Villemagne, B; Willand, N	1
Cierpicki, T; Franzblau, SG; Garcia, GA; Gill, SK; Kirchhoff, PD; Peng, KW; Showalter, HD; Turbiak, AJ; Wan, B; Xu, H; Zhang, N	1
Chibale, K; Franzblau, SG; Gut, J; Little, S; Rosenthal, PJ; Tukulula, M; Wan, B	1
Ammerman, NC; Bishai, WR; Chen, G; Gunosewoyo, H; Guo, H; Kozikowski, AP; Lun, S; Onajole, OK; Pieroni, M; Stec, J; Tipparaju, SK	1
Barry, CE; Dartois, V	1
Alling, T; Bailey, M; Boshoff, H; Cramer, J; Hipskind, PA; Markley, LD; Miller, MJ; Moraski, GC; Ollinger, J; Parish, T	1
Cho, SH; Franzblau, SG; Fryling, NA; Hwang, CH; Jaki, BU; Klein, LL; Lankin, DC; McAlpine, JB; Napolitano, JG; Pauli, GF; Stamets, PE; Wang, Y	1
Cho, S; Costantino, G; Franzblau, SG; Pieroni, M; Wan, B	1
Cho, S; Franzblau, SG; Markley, LD; Miller, MJ; Moraski, GC; Oliver, AG	1
Dufková, I; Hrabálek, A; Karabanovich, G; Klimešová, V; Němeček, J; Pávek, P; Roh, J; Smutný, T; Stolaříková, J; Vávrová, K; Vejsová, M; Vicherek, P	1
Biava, M; Cocozza, M; Consalvi, S; Poce, G	1
Azad, AK; Balada-Llasat, JM; Chen, CS; Kapuriya, NP; Pancholi, P; Salunke, SB; Schlesinger, LS	1
Camacho, LR; Diagana, TT; Goh, A; Herve, M; Kondreddi, RR; Ma, NL; Manjunatha, UH; Ng, PS; Noble, CG; Peukert, S; Rao, SP; Smith, PW	1
Bloomer, WD; Kaiser, M; Papadopoulou, MV; Rosenzweig, HS	1
Franzblau, SG; Hu, X; Liu, Z; Lu, X; Wan, B; Wang, R; You, Q; Zhang, T	1
Ang, CW; Avery, VM; Blaskovich, MAT; Butler, MS; Cooper, MA; Debnath, A; Hahn, HJ; Jarrad, AM; Jones, AJ; Karoli, T; Pelingon, R; Sykes, ML; Tan, L; West, NP; Woods, K	1
Dušek, J; Hrabálek, A; Huszár, S; Jand'ourek, O; Karabanovich, G; Klimešová, V; Kočová Vlčková, H; Konečná, K; Konyariková, Z; Korábečný, J; Korduláková, J; Kučera, T; Mikušová, K; Pávek, P; Pávková, I; Pavliš, O; Roh, J; Savková, K; Stolaříková, J; Vávrová, K	1
Mabhula, A; Singh, V	1
Boshoff, HIM; Caljon, G; Forbes, HE; Hulpia, F; Jian, Y; Munier-Lehmann, H; Risseeuw, MDP; Van Calenbergh, S	1
Ang, CW; Avery, VM; Bernhardt, PV; Blaskovich, MAT; Bolisetti, R; Cooper, MA; Francisco, AF; Franzblau, SG; Hinton, AO; Jackson, CJ; Kelly, JM; Lee, BM; Sykes, ML; Tan, L; Wang, Y; West, NP	1
Almeida, D; Bishai, WR; Grosset, JH; Nuermberger, E; Peloquin, CA; Rosenthal, I; Tyagi, S; Williams, KN	1
Zhang, Y	1
Grosset, J; Nuermberger, E; Tasneen, R; Tyagi, S; Williams, K	1
Cole, ST; Dhar, N; Ha, YH; Hartkoorn, RC; Sala, C; Schneider, P; Zhang, M	1
Becker, P; Dawson, R; Diacon, AH; Donald, PR; du Bois, J; Erondu, N; Ginsberg, AM; Narunsky, K; Spigelman, MK; van Niekerk, C; Venter, A	1
Amoabeng, O; Andries, K; Mdluli, KE; Minkowski, A; Nuermberger, EL; Peloquin, CA; Taylor, D; Wallis, RS; Williams, K	1
Cole, ST; Hartkoorn, RC; Lechartier, B	1
Dutta, NK; Karakousis, PC	1
Burger, DA; Conradie, A; Dawson, R; Diacon, AH; Donald, PR; Eisenach, K; Everitt, D; Ive, P; Mendel, CM; Ntinginya, NE; Page-Shipp, L; Pym, A; Reither, K; Schall, R; Spigelman, M; van Niekerk, C; Variava, E; Venter, A; von Groote-Bidlingmaier, F	1
Mendel, C; Murray, S; Spigelman, M	1
Fattorini, L; Giannoni, F; Iacobino, A; Pardini, M; Piccaro, G	1
Barnes, G; Dawson, R; Dooley, KE; Dorman, SE; Friedman, A; Gupte, N; Hendricks, B; Ignatius, EH; Narunsky, K; Smit, T; Whitelaw, C	1

Reviews

5 review(s) available for isoniazid and pa 824

Article	Year
Tuberculosis: the drug development pipeline at a glance. European journal of medicinal chemistry, 2012, Volume: 51 Topics: Animals; Antitubercular Agents; Clinical Trials as Topic; Drug Discovery; Humans; Tuberculosis	2012
A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis. Bioorganic & medicinal chemistry letters, 2013, Sep-01, Volume: 23, Issue:17 Topics: Animals; Antitubercular Agents; Drug Discovery; Humans; Lung; Mycobacterium tuberculosis; Tuberculosis	2013
SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development. European journal of medicinal chemistry, 2014, Oct-30, Volume: 86 Topics: Animals; Antitubercular Agents; Humans; Mycobacterium tuberculosis; Structure-Activity Relationship; Tuberculosis; Tuberculosis, Multidrug-Resistant	2014
Drug-resistance in MedChemComm, 2019, Aug-01, Volume: 10, Issue:8 Topics:	2019
Advances in the treatment of tuberculosis. Clinical pharmacology and therapeutics, 2007, Volume: 82, Issue:5 Topics: Adamantane; AIDS-Related Opportunistic Infections; Animals; Anti-Bacterial Agents; Antitubercular Agents; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Drugs, Investigational; Ethylenediamines; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Humans; Isoniazid; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pyrazinamide; Rifampin; Treatment Refusal; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2007

Trials

3 trial(s) available for isoniazid and pa 824

Article	Year
Phase II dose-ranging trial of the early bactericidal activity of PA-824. Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:6 Topics: Adolescent; Adult; Antitubercular Agents; Drug Administration Schedule; Ethambutol; Female; Humans; Isoniazid; Male; Middle Aged; Nitroimidazoles; Pyrazinamide; Rifampin; Tuberculosis, Pulmonary; Young Adult	2012
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pul Lancet (London, England), 2015, May-02, Volume: 385, Issue:9979 Topics: Adolescent; Adult; Antitubercular Agents; Colony Count, Microbial; Drug Therapy, Combination; Ethambutol; Female; Fluoroquinolones; Humans; Isoniazid; Male; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Rifampin; South Africa; Sputum; Tanzania; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Young Adult	2015
Assessing Pretomanid for Tuberculosis (APT), a Randomized Phase 2 Trial of Pretomanid-Containing Regimens for Drug-Sensitive Tuberculosis: 12-Week Results. American journal of respiratory and critical care medicine, 2023, 04-01, Volume: 207, Issue:7 Topics: Animals; Antitubercular Agents; Drug Therapy, Combination; Isoniazid; Mice; Nitroimidazoles; Pyrazinamide; Rifampin; Tuberculosis, Pulmonary	2023

Other Studies

38 other study(ies) available for isoniazid and pa 824

Article	Year
A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature, 2000, Jun-22, Volume: 405, Issue:6789 Topics: Animals; Antitubercular Agents; Bacterial Proteins; Drug Resistance, Microbial; Drug Resistance, Multiple; Guinea Pigs; Lipids; Metronidazole; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Structure-Activity Relationship; Tuberculosis	2000
OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS medicine, 2006, Volume: 3, Issue:11 Topics: Animals; Antitubercular Agents; Blood; Cell Line; Humans; In Vitro Techniques; Intracellular Membranes; Macrophages; Mammals; Mice; Microbial Sensitivity Tests; Microsomes, Liver; Mycobacterium; Mycobacterium bovis; Mycolic Acids; Nitroimidazoles; Oxazoles; Treatment Outcome; Tuberculosis	2006
Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:4 Topics: Anti-Bacterial Agents; Antitubercular Agents; DNA, Bacterial; Drug Evaluation, Preclinical; Mycobacterium tuberculosis; Oxygen	2007
Efficacy of quinoxaline-2-carboxylate 1,4-di-N-oxide derivatives in experimental tuberculosis. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:9 Topics: Animals; Antitubercular Agents; Cyclic N-Oxides; Disease Models, Animal; Drug Resistance, Bacterial; Female; Humans; Lung; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Quinoxalines; Specific Pathogen-Free Organisms; Spleen; Structure-Activity Relationship; Treatment Outcome; Tuberculosis, Pulmonary	2008
Rational design of 5-phenyl-3-isoxazolecarboxylic acid ethyl esters as growth inhibitors of Mycobacterium tuberculosis. a potent and selective series for further drug development. Journal of medicinal chemistry, 2010, Jan-28, Volume: 53, Issue:2 Topics: Animals; Antitubercular Agents; Chlorocebus aethiops; Drug Design; Drug Resistance, Bacterial; Esters; Isoxazoles; Mycobacterium tuberculosis; Structure-Activity Relationship; Vero Cells	2010
Synthesis, antimalarial and antitubercular activity of acetylenic chalcones. Bioorganic & medicinal chemistry letters, 2010, Feb-01, Volume: 20, Issue:3 Topics: Alkynes; Antimalarials; Antitubercular Agents; Chalcones; Mycobacterium tuberculosis; Plasmodium falciparum	2010
Synthesis of non-purine analogs of 6-aryl-9-benzylpurines, and their antimycobacterial activities. Compounds modified in the imidazole ring. Bioorganic & medicinal chemistry, 2010, Oct-15, Volume: 18, Issue:20 Topics: Animals; Anti-Bacterial Agents; Chlorocebus aethiops; Drug Resistance, Bacterial; Imidazoles; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Purines; Vero Cells	2010
Novel thiolactone-isatin hybrids as potential antimalarial and antitubercular agents. Bioorganic & medicinal chemistry letters, 2011, Apr-01, Volume: 21, Issue:7 Topics: Animals; Antimalarials; Antitubercular Agents; Isatin; Lactones; Mycobacterium tuberculosis; Plasmodium falciparum; Structure-Activity Relationship	2011
Facile transformation of Biginelli pyrimidin-2(1H)-ones to pyrimidines. In vitro evaluation as inhibitors of Mycobacterium tuberculosis and modulators of cytostatic activity. European journal of medicinal chemistry, 2011, Volume: 46, Issue:6 Topics: Animals; Antitubercular Agents; Cell Proliferation; Drug Screening Assays, Antitumor; HeLa Cells; Humans; Mice; Molecular Structure; Mycobacterium tuberculosis; Pyrimidines; Stereoisomerism; Structure-Activity Relationship; Tumor Cells, Cultured	2011
Synthesis and antimycobacterial activities of non-purine analogs of 6-aryl-9-benzylpurines: Imidazopyridines, pyrrolopyridines, benzimidazoles, and indoles. Bioorganic & medicinal chemistry, 2011, Jun-01, Volume: 19, Issue:11 Topics: Animals; Antitubercular Agents; Benzimidazoles; Chlorocebus aethiops; Imidazoles; Indoles; Mycobacterium tuberculosis; Purines; Pyridines; Vero Cells	2011
Advent of Imidazo[1,2-a]pyridine-3-carboxamides with Potent Multi- and Extended Drug Resistant Antituberculosis Activity. ACS medicinal chemistry letters, 2011, Jun-09, Volume: 2, Issue:6 Topics:	2011
Synthesis and structure-activity relationships of novel substituted 8-amino, 8-thio, and 1,8-pyrazole congeners of antitubercular rifamycin S and rifampin. Bioorganic & medicinal chemistry letters, 2011, Oct-15, Volume: 21, Issue:20 Topics: Antitubercular Agents; Escherichia coli; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Pyrazoles; Rifampin; Rifamycins; Tuberculosis	2011
Synthesis and evaluation of anti-tubercular and antibacterial activities of new 4-(2,6-dichlorobenzyloxy)phenyl thiazole, oxazole and imidazole derivatives. Part 2. European journal of medicinal chemistry, 2012, Volume: 49 Topics: Anti-Bacterial Agents; Antitubercular Agents; Bacteria; Bacterial Infections; Humans; Imidazoles; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Oxazoles; Thiazoles; Tuberculosis	2012
Generation and exploration of new classes of antitubercular agents: The optimization of oxazolines, oxazoles, thiazolines, thiazoles to imidazo[1,2-a]pyridines and isomeric 5,6-fused scaffolds. Bioorganic & medicinal chemistry, 2012, Apr-01, Volume: 20, Issue:7 Topics: Antitubercular Agents; Isomerism; Isoxazoles; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Oxazoles; Pyridines; Structure-Activity Relationship; Thiazoles	2012
Structure-based design of novel benzoxazinorifamycins with potent binding affinity to wild-type and rifampin-resistant mutant Mycobacterium tuberculosis RNA polymerases. Journal of medicinal chemistry, 2012, Apr-26, Volume: 55, Issue:8 Topics: Animals; Antibiotics, Antitubercular; Benzoxazines; DNA-Directed RNA Polymerases; Drug Design; Drug Resistance, Bacterial; Mice; Mycobacterium tuberculosis; Rifampin; Rifamycins	2012
The design, synthesis, in silico ADME profiling, antiplasmodial and antimycobacterial evaluation of new arylamino quinoline derivatives. European journal of medicinal chemistry, 2012, Volume: 57 Topics: Aminoquinolines; Antiprotozoal Agents; Antitubercular Agents; Biological Assay; Blood-Brain Barrier; Computer Simulation; Drug Design; Erythrocytes; Humans; Inhibitory Concentration 50; Mefloquine; Microbial Sensitivity Tests; Models, Biological; Mycobacterium tuberculosis; Plasmodium falciparum; Quinine; Structure-Activity Relationship; Tetrazoles	2012
Preliminary structure-activity relationships and biological evaluation of novel antitubercular indolecarboxamide derivatives against drug-susceptible and drug-resistant Mycobacterium tuberculosis strains. Journal of medicinal chemistry, 2013, May-23, Volume: 56, Issue:10 Topics: Animals; Antitubercular Agents; Cell Survival; Chlorocebus aethiops; Colony Count, Microbial; Drug Design; Drug Resistance, Bacterial; Female; High-Throughput Screening Assays; Indoles; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Serum Bactericidal Test; Solubility; Structure-Activity Relationship; Vero Cells	2013
Advancement of Imidazo[1,2- ACS medicinal chemistry letters, 2013, Jul-11, Volume: 4, Issue:7 Topics:	2013
Chlorinated coumarins from the polypore mushroom Fomitopsis officinalis and their activity against Mycobacterium tuberculosis. Journal of natural products, 2013, Oct-25, Volume: 76, Issue:10 Topics: Agaricales; Animals; Antitubercular Agents; Chlorocebus aethiops; Coumarins; Cytotoxins; Hydrocarbons, Chlorinated; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Nuclear Magnetic Resonance, Biomolecular; Vero Cells	2013
Design, synthesis and investigation on the structure-activity relationships of N-substituted 2-aminothiazole derivatives as antitubercular agents. European journal of medicinal chemistry, 2014, Jan-24, Volume: 72 Topics: Animals; Antitubercular Agents; Chlorocebus aethiops; Dose-Response Relationship, Drug; Drug Design; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Structure-Activity Relationship; Thiazoles; Tuberculosis; Vero Cells	2014
Scaffold-switching: an exploration of 5,6-fused bicyclic heteroaromatics systems to afford antituberculosis activity akin to the imidazo[1,2-a]pyridine-3-carboxylates. Bioorganic & medicinal chemistry letters, 2014, Aug-01, Volume: 24, Issue:15 Topics: Antitubercular Agents; Bridged Bicyclo Compounds; Dose-Response Relationship, Drug; Heterocyclic Compounds; Hydrocarbons, Aromatic; Imidazoles; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Pyridines; Pyrimidines; Structure-Activity Relationship	2014
1-Substituted-5-[(3,5-dinitrobenzyl)sulfanyl]-1H-tetrazoles and their isosteric analogs: A new class of selective antitubercular agents active against drug-susceptible and multidrug-resistant mycobacteria. European journal of medicinal chemistry, 2014, Jul-23, Volume: 82 Topics: Antineoplastic Agents; Antitubercular Agents; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Multiple, Bacterial; Drug Screening Assays, Antitumor; HeLa Cells; Hep G2 Cells; Humans; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Nitrobenzenes; Structure-Activity Relationship; Triazoles; Tumor Cells, Cultured	2014
Design and synthesis of novel anti-tuberculosis agents from the celecoxib pharmacophore. Bioorganic & medicinal chemistry, 2015, May-01, Volume: 23, Issue:9 Topics: Antitubercular Agents; Celecoxib; Dose-Response Relationship, Drug; Drug Design; Drug Resistance, Multiple, Bacterial; Healthy Volunteers; Humans; Macrophages; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium smegmatis; Mycobacterium tuberculosis; Structure-Activity Relationship	2015
Structure activity relationships of 4-hydroxy-2-pyridones: A novel class of antituberculosis agents. European journal of medicinal chemistry, 2015, Dec-01, Volume: 106 Topics: Animals; Antitubercular Agents; Biological Availability; Dose-Response Relationship, Drug; Drug Stability; Humans; Mice; Microbial Sensitivity Tests; Microsomes, Liver; Models, Molecular; Molecular Structure; Mycobacterium tuberculosis; Pyridones; Rats; Structure-Activity Relationship; Tuberculosis, Multidrug-Resistant	2015
The antitrypanosomal and antitubercular activity of some nitro(triazole/imidazole)-based aromatic amines. European journal of medicinal chemistry, 2017, Sep-29, Volume: 138 Topics: Amines; Antitubercular Agents; Dose-Response Relationship, Drug; Imidazoles; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Nitro Compounds; Parasitic Sensitivity Tests; Structure-Activity Relationship; Triazoles; Trypanocidal Agents; Trypanosoma brucei rhodesiense; Trypanosoma cruzi	2017
Benzylsulfanyl benzo-heterocycle amides and hydrazones as new agents against drug-susceptible and resistant MedChemComm, 2017, Jun-01, Volume: 8, Issue:6 Topics:	2017
Design, Synthesis, and Biological Evaluation of 2-Nitroimidazopyrazin-one/-es with Antitubercular and Antiparasitic Activity. Journal of medicinal chemistry, 2018, 12-27, Volume: 61, Issue:24 Topics: Animals; Antiparasitic Agents; Antitubercular Agents; Caco-2 Cells; Drug Design; Drug Evaluation, Preclinical; Drug Stability; Entamoeba histolytica; Giardia lamblia; Humans; Mice; Microbial Sensitivity Tests; Microsomes, Liver; Nitroimidazoles; Structure-Activity Relationship	2018
Development of 3,5-Dinitrophenyl-Containing 1,2,4-Triazoles and Their Trifluoromethyl Analogues as Highly Efficient Antitubercular Agents Inhibiting Decaprenylphosphoryl-β-d-ribofuranose 2'-Oxidase. Journal of medicinal chemistry, 2019, 09-12, Volume: 62, Issue:17 Topics: Alcohol Oxidoreductases; Antitubercular Agents; Bacterial Proteins; Dinitrobenzenes; Dose-Response Relationship, Drug; Drug Development; Hydrocarbons, Fluorinated; Models, Molecular; Molecular Structure; Mycobacterium tuberculosis; Structure-Activity Relationship; Triazoles	2019
2-((3,5-Dinitrobenzyl)thio)quinazolinones: Potent Antimycobacterial Agents Activated by Deazaflavin (F Journal of medicinal chemistry, 2021, 01-14, Volume: 64, Issue:1 Topics: Antitubercular Agents; High-Throughput Screening Assays; Microbial Sensitivity Tests; Mutagenicity Tests; Mycobacterium tuberculosis; Nitroreductases; Quinazolinones; Riboflavin; Structure-Activity Relationship	2021
Nitroimidazopyrazinones with Oral Activity against Tuberculosis and Chagas Disease in Mouse Models of Infection. Journal of medicinal chemistry, 2022, 10-13, Volume: 65, Issue:19 Topics: Animals; Chagas Disease; Disease Models, Animal; Mice; Mycobacterium tuberculosis; Nitroimidazoles; Nitroreductases; Trypanosoma cruzi; Tuberculosis	2022
Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis. Antimicrobial agents and chemotherapy, 2006, Volume: 50, Issue:8 Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Disease Models, Animal; Drug Therapy, Combination; Ethambutol; Female; Isoniazid; Mice; Mice, Inbred BALB C; Mycobacterium tuberculosis; Nitroimidazoles; Pyrazinamide; Rifampin; Secondary Prevention; Time Factors; Tuberculosis, Pulmonary	2006
Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:10 Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Colony Count, Microbial; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Female; Isoniazid; Lung; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Nitroimidazoles; Pyrazinamide; Recurrence; Rifampin; Tuberculosis, Pulmonary	2008
Simple model for testing drugs against nonreplicating Mycobacterium tuberculosis. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:10 Topics: Antitubercular Agents; Aza Compounds; Fluoroquinolones; Isoniazid; Meropenem; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Quinolines; Rifampin; Streptomycin; Thienamycins	2010
Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis. Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:6 Topics: Animals; Antitubercular Agents; Drug Therapy, Combination; Female; Isoniazid; Mice; Mice, Inbred BALB C; Mycobacterium tuberculosis; Nitroimidazoles; Oxazolidinones; Pyrazinamide; Rifampin; Tuberculosis; Tuberculosis, Multidrug-Resistant	2012
In vitro combination studies of benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis. Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:11 Topics: Adamantane; Antitubercular Agents; Aza Compounds; Diarylquinolines; Drug Combinations; Drug Synergism; Ethambutol; Ethylenediamines; Fluoroquinolones; Isoniazid; Meropenem; Microbial Sensitivity Tests; Microbial Viability; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Quinolines; Rifampin; Spiro Compounds; Thiazines; Thienamycins	2012
PA-824 is as effective as isoniazid against latent tuberculosis infection in C3HeB/FeJ mice. International journal of antimicrobial agents, 2014, Volume: 44, Issue:6 Topics: Animals; Antitubercular Agents; Disease Models, Animal; Female; Isoniazid; Latent Tuberculosis; Lung; Mice; Mice, Inbred C3H; Mycobacterium tuberculosis; Nitroimidazoles; Rifampin	2014
TB Alliance regimen development for multidrug-resistant tuberculosis. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2016, 12-01, Volume: 20, Issue:12 Topics: Antitubercular Agents; Clinical Protocols; Diarylquinolines; Dose-Response Relationship, Drug; Ethambutol; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Humans; Isoniazid; Linezolid; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Randomized Controlled Trials as Topic; Research Design; Rifampin; Tuberculosis, Multidrug-Resistant	2016
The Combination Rifampin-Nitazoxanide, but Not Rifampin-Isoniazid-Pyrazinamide-Ethambutol, Kills Dormant Mycobacterium tuberculosis in Hypoxia at Neutral pH. Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:7 Topics: Antitubercular Agents; Drug Combinations; Drug Therapy, Combination; Ethambutol; Humans; Hydrogen-Ion Concentration; Hypoxia; Isoniazid; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazolidinones; Pyrazinamide; Rifampin; Tuberculosis	2019

chemdatabank.com